Login / Signup

A critical assessment of bioactive compounds databases.

Daniela Quadros de AzevedoBeatriz Mattos CampioniFelipe Augusto Pedroz LimaJosé Luis Medina-FrancoRachel Oliveira CastilhoVinícius Gonçalves Maltarollo
Published in: Future medicinal chemistry (2024)
Compound databases (DBs) are essential tools for drug discovery. The number of DBs in public domain is increasing, so it is important to analyze these DBs. In this article, the main characteristics of 64 DBs will be presented. The methodological strategy used was a literature search. To analyze the characteristics obtained in the review, the DBs were categorized into two subsections: Open Access and Commercial DBs. Open access includes generalist DBs (containing compounds of diverse origins), DBs with specific applicability, DBs exclusive to natural products and those containing compounds with specific pharmacological action. The literature review showed that there are challenges to making these repositories available, such as standardizing information curation practices and funding to maintain and sustain them.
Keyphrases
  • deep brain stimulation
  • healthcare
  • drug discovery
  • systematic review
  • primary care
  • minimally invasive
  • emergency department
  • big data
  • artificial intelligence
  • health information
  • adverse drug